Shubulade Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4214197/publications.pdf

Version: 2024-02-01

57 papers

2,090 citations

20 h-index 243625 44 g-index

57 all docs

57 docs citations

57 times ranked

2849 citing authors

#	Article	IF	CITATIONS
1	Dietary intake, physical activity and sedentary behaviour patterns in a sample with established psychosis and associations with mental health symptomatology. Psychological Medicine, 2023, 53, 1565-1575.	4.5	15
2	Vitamin D and cardiometabolic outcomes in first episode psychosis (FEP): A prospective cohort study. Schizophrenia Research, 2022, 246, 26-29.	2.0	0
3	Advance directives reduce friction over involuntary treatment. Lancet Psychiatry, the, 2021, 8, 749.	7.4	O
4	Predictive value of cardiometabolic biomarkers and depressive symptoms for symptom severity and quality of life in patients with psychotic disorders. Journal of Affective Disorders, 2021, 298, 95-103.	4.1	2
5	Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis. JAMA Network Open, 2021, 4, e2140858.	5.9	14
6	Reasons behind the rising rate of involuntary admissions under the Mental Health Act (1983): Service use and cost impact. International Journal of Law and Psychiatry, 2020, 68, 101506.	0.9	16
7	T183. LOW LEVELS OF VITAMIN D ARE ASSOCIATED WITH REDUCED CORTICAL THICKNESS AND SURFACE AREA IN FRONTAL, TEMPORAL AND OCCIPITAL REGIONS IN FIRST-EPISODE PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2020, 46, S301-S302.	4.3	O
8	Clozapine and COVID-19. BJPsych Bulletin, 2020, 44, 179-180.	1.1	6
9	Understanding increasing rates of psychiatric hospital detentions in England: development and preliminary testing of an explanatory model. BJPsych Open, 2020, 6, e88.	0.7	9
10	Potential gains in life expectancy from reducing amenable mortality among people diagnosed with serious mental illness in the United Kingdom. PLoS ONE, 2020, 15, e0230674.	2.5	22
11	Multidisciplinary research priorities for the COVID-19 pandemic. Lancet Psychiatry, the, 2020, 7, e40.	7.4	11
12	Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial. Trials, 2020, 21, 14.	1.6	10
13	A health promotion intervention to improve lifestyle choices and health outcomes in people with psychosis: a research programme including the IMPaCT RCT. Programme Grants for Applied Research, 2020, 8, 1-124.	1.0	3
14	Title is missing!. , 2020, 15, e0230674.		0
15	Title is missing!. , 2020, 15, e0230674.		0
16	Title is missing!. , 2020, 15, e0230674.		0
17	Title is missing!. , 2020, 15, e0230674.		O
18	Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study. British Journal of Psychiatry, 2019, 215, 712-719.	2.8	25

#	Article	IF	Citations
19	Tobacco smoking and nicotine dependence in first episode and established psychosis. Asian Journal of Psychiatry, 2019, 43, 125-131.	2.0	25
20	Outcome of a psychosocial health promotion intervention aimed at improving physical health and reducing alcohol use in patients with schizophrenia and psychotic disorders (MINT). Schizophrenia Research, 2019, 208, 138-144.	2.0	6
21	Ethnic variations in compulsory detention under the Mental Health Act: a systematic review and meta-analysis of international data. Lancet Psychiatry,the, 2019, 6, 305-317.	7.4	135
22	Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study. Schizophrenia Research, 2019, 204, 381-388.	2.0	16
23	The Future of Psychiatry Commission – Authors' reply. Lancet Psychiatry,the, 2018, 5, 17-18.	7.4	2
24	O5.2. PREDICTORS OF CARDIOMETABOLIC RISK IN THE YEAR AFTER ONSET OF PSYCHOSIS: A PROSPECTIVE COHORT STUDY. Schizophrenia Bulletin, 2018, 44, S87-S87.	4.3	O
25	The Representativeness of Participants With Severe Mental Illness in a Psychosocial Clinical Trial. Frontiers in Psychiatry, 2018, 9, 654.	2.6	22
26	The WPA- Lancet Psychiatry Commission on the Future of Psychiatry. Lancet Psychiatry, the, 2017, 4, 775-818.	7.4	305
27	An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. Biological Psychiatry, 2017, 81, 470-477.	1.3	176
28	Translation and cross-cultural adaptation of the Sexual Function Questionnaire (SFQ) into Brazilian Portuguese. Trends in Psychiatry and Psychotherapy, 2017, 39, 110-115.	0.8	6
29	Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotion. BMC Psychiatry, 2017, 17, 407.	2.6	10
30	Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT). BMC Psychiatry, 2017, 17, 413.	2.6	39
31	Pain is independently associated with reduced health related quality of life in people with psychosis. Psychiatry Research, 2015, 230, 585-591.	3.3	15
32	Does environmental confounding mask pleiotropic effects of a multiple sclerosis susceptibility variant on vitamin D in psychosis?. NPJ Schizophrenia, 2015, 1, 15036.	3.6	0
33	Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis. Schizophrenia Research, 2015, 168, 461-464.	2.0	48
34	Vitamin D deficiency in first episode psychosis: A case–control study. Schizophrenia Research, 2013, 150, 533-537.	2.0	76
35	Improving physical health and reducing substance use in psychosis $\hat{a} \in \text{``randomised control trial'}$ (IMPACT RCT): study protocol for a cluster randomised controlled trial. BMC Psychiatry, 2013, 13, 263.	2.6	28
36	Sexual dysfunction in people with prodromal or first-episode psychosis. British Journal of Psychiatry, 2012, 201, 131-136.	2.8	46

#	Article	IF	Citations
37	Sexuality in psychosis: dysfunction, risk and mental capacity. Advances in Psychiatric Treatment, 2011, 17, 275-282.	0.5	4
38	Gender differences in antipsychotic prescribing. International Review of Psychiatry, 2010, 22, 472-484.	2.8	65
39	Metabolic syndrome common in people with psychotic disorders, particularly in users of high potency antipsychotics. Evidence-Based Mental Health, 2008, 11, 62-62.	4.5	0
40	A well-being programme in severe mental illness. reducing risk for physical ill-health: A post-programme service evaluation at 2 years. European Psychiatry, 2007, 22, 413-418.	0.2	84
41	Drugs that cause sexual dysfunction. Psychiatry (Abingdon, England), 2007, 6, 111-114.	0.2	23
42	Sexual Function and Gonadal Hormones in Patients Taking Antipsychotic Treatment for Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2007, 68, 361-367.	2.2	77
43	The Relationship Between Prolactin Levels and Glucose Homeostasis in Antipsychotic-treated Schizophrenic Patients. Journal of Clinical Psychopharmacology, 2006, 26, 629-631.	1.4	9
44	Bone Mineral Density and Its Relationship to Prolactin Levels in Patients Taking Antipsychotic Treatment. Journal of Clinical Psychopharmacology, 2005, 25, 259-261.	1.4	57
45	Comments on "Prolactin Levels and Erectile Function in Patients Treated With Risperidone" (J Clin) Tj ETQq1 1 C).784314 r 1.4	gBT ₁ /Overlock
46	Prescribing for erectile dysfunction: A Delphi based consensus study. Sexual and Relationship Therapy, 2005, 20, 181-194.	1.2	2
47	Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry, 2004, 184, 503-508.	2.8	198
48	Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Current Medical Research and Opinion, 2004, 20, 1649-1649.	1.9	5
49	Drugs that cause sexual dysfunction. Psychiatry (Abingdon, England), 2004, 3, 20-22.	0.2	0
50	Title is missing!. Journal of Clinical Psychopharmacology, 2003, 23, S27-S32.	1.4	7
51	Effects of Antipsychotics on Sexual and Endocrine Function in Women: Implications for Clinical Practice. Journal of Clinical Psychopharmacology, 2003, 23, S27-S32.	1.4	27
52	Sexual dysfunction in patients taking conventional antipsychotic medication. British Journal of Psychiatry, 2002, 181, 49-55.	2.8	241
53	The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis. Journal of Clinical Psychopharmacology, 2002, 22, 109-114.	1.4	170
54	Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. BMJ, The, 2002, 324, 1278.	6.0	3

SHUBULADE SMITH

#	Article	IF	CITATIONS
55	What you don't know won't hurt you. Psychiatric Bulletin, 2000, 24, 172-174.	0.3	21
56	Mental health review tribunal medical reports. Psychiatric Bulletin, 1998, 22, 615-618.	0.3	8
57	Treating women with schizophrenia., 0,, 307-319.		O